Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Government-private Sector Dialogue Begins
February 5, 2007
- Kansai Bio-Cluster Is No. 4 in the World: Prof. Morishita
February 5, 2007
- PM Abe Calls For Strategic Support of Pharma Industry in Policy Speech
February 5, 2007
- Mochida Aims to Become Specialty Pharma Focused in 4 Fields
February 5, 2007
- REGULATORY NEWS IN BRIEF
February 5, 2007
- Course and Strategy for Japanese Economy Approved by Cabinet
February 5, 2007
- Pfizer Embarks on Major Restructuring
February 5, 2007
- COMMENTARY From Convoy System to Competition
February 5, 2007
- Health Minister Yanagisawa Sees Need for Gov't to Prevent Buy-outs
February 5, 2007
- TOPICS 2 articles
February 5, 2007
- Council Calls For Rapid Development of Alemtuzumab, Talc
February 5, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 5, 2007
- Add'l Indications Recommended for Valtrex, Glivec
February 5, 2007
- MEXT to Strengthen Anticancer Efforts in FY2007
February 5, 2007
- Pfizer Japan, Astellas Announce Approval of Celecox
February 5, 2007
- Saiseikai Group to Initiate Study in Preparation for Joint Purchasing
February 5, 2007
- New Industry Vision to Focus on Environment for Drug Discovery: EAD Director
February 5, 2007
- MEDICAL DEVICE NEWS IN BRIEF
February 5, 2007
- Global Companies Move toClose Research Lab in Japan
February 5, 2007
- GE Healthcare Bio-Sciences Announces Tie-up with Effector Cell Institute
February 5, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…